PD-L1表达阳性的复发性转移性阴茎癌患者从免疫治疗中获得显著获益：一例报告及文献复习
Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review.
作者信息
Su Xiangyu, Zhang Jing, Fu Chenchun, Xiao Mingzhe, Wang Cailian
机构信息
Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, People's Republic of China.
Department of Oncology, The Second People's Hospital of Taizhou City, Taizhou, Zhejiang, People's Republic of China.
出版信息
Onco Targets Ther. 2020 Apr 21;13:3319-3324. doi: 10.2147/OTT.S231258. eCollection 2020.
BACKGROUND
Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed.
CASE PRESENTATION
We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months.
CONCLUSION
This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions.
背景
阴茎鳞状细胞癌（PSCC）因其罕见性和有限的治疗选择，尤其是在标准治疗失败后，预后较差。迫切需要有效的治疗选择。
病例报告
我们报告了一例复发性转移性PSCC患者，其程序性死亡配体1（PD-L1）表达阳性（≥10%），肿瘤突变负荷（TMB）为8.87（突变数/百万碱基），该患者对免疫治疗获得了显著反应，无进展生存期（PFS）超过10个月。
结论
这是首例在中国PSCC患者中对免疫治疗呈现显著反应的病例。该显著反应可能与PD-L1表达有关，表明PD-L1表达可能是PSCC免疫治疗的一个有前景的生物标志物。TMB排名也可能有助于患者选择。然而，需要大型临床试验来验证这些观点。
Zotero 插件